Pharmaceutical Industry discussion, review, analysis, news and information. |
« GTx, Inc. Entered Partnership Agreement with Ipsen for Acapodene®’s European Rights | Main | Jazz Pharmaceuticals Initiated Phase III Clinical Trial of Xyrem® (Sodium Oxybate) in Fibromyalgia Syndrome Patients »
|
Sep11
|
 A drug and diagnostic discovery company, ExonHit Therapeutics S.A. (EPA: ALEHT), has granted Merck & Co., Inc. (NYSE: MRK) a non-exclusive license to rights for research only under Patent US 6,881,571, where it is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.
Patent
Source: PR Newswire |
TrackBack URL for this entry:
« GTx, Inc. Entered Partnership Agreement with Ipsen for Acapodene®’s European Rights | Main | Jazz Pharmaceuticals Initiated Phase III Clinical Trial of Xyrem® (Sodium Oxybate) in Fibromyalgia Syndrome Patients »
Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!
BIZZlogos - Add your logo - free link to your site| View Network Map Network Feed List (OPML) Know More Media Network Feed |
PharmaGazette is a member of the Know More Media network of business related blogs.
Here are some current headlines from some of our business publications:
ProductivityGoal | CallCenterScript |
AdHurl | TheBizofKnowledge |
LandingTheDeal | CustomersAreAlways |
HealthCareVox | BrainBasedBusiness |
TheInsurancePolicy | MarketingBlurb |
Write for us About us Contact Advertise Privacy Disclaimer
This weblog is licensed under a Creative Commons License.
Comment Preview